Published in Clinical Oncology Week, August 21st, 2006
"TaraC is in phase I development for treatment of cancer," wrote M.L. Clarke and colleagues, Cross Cancer Institute.
"In human equilibrative nucleoside transporter (hENT) 1-containing CEM cells, initial rates of uptake (10 mcM; picomoles per microliter of cell water per second) of [H-3] TaraC and [H-3] araC were low (0.007±003 and 0.034±0.003, respectively) compared with that of [H-3] uridine (0.317±0.048), a high-activity...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.